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Introduction
• Metastatic prostate cancer is associated with significant morbidity and 
poor overall survival. 
• Recent analysis of the National Cancer Database showed that local 
treatment in metastatic prostate cancer may be associated with better 3-
year overall survival compared to no local treatment.
• Clinical trials are currently examining the role of primary radiation or 
radical prostatectomy (RP) in this setting. 
• While the safety of RP in localized prostate cancer is proven, few studies 
have looked at perioperative complication rates and cost of cytoreductive 
RP at a national level. 
Methods
•Database used: Healthcare Cost and Utilization Project National Inpatient Sample (NIS)
• Patient cohort: A total of 91,835 records met inclusion criteria 
(estimated 454,860 RPs per NIS survey weights). Of these 1,173 had 
cytoreductive RP (Estimated 5,835 cases). 
• Primary Outcome: Inpatient complications 
• Secondary outcomes: In-hospital mortality, individual complications, 
length of hospital stay, and total cost. 
• HCUP cost-to-charge files were used to calculate total cost, which was 
inflation-adjusted to 2014 dollars 
• Covariates: Age, race, Charlson Comorbidity score, insurance status, 
rural/semi-urban/urban location, income, hospital location (rural/urban), 
hospital teaching status, geographical location, and hospital volume
Methods
• Any inpatient complications occurred in 14.9% records; This number was 
higher in patients undergoing cytoreductive RP [19.1% vs. 14.9% in the 
nonmetastatic group; p=0.008]. 
• On multivariable analysis, presence of metastasis was an independent 
predictor for any complications (Odds ratio [Confidence interval] 1.329 
[1.077-1.640] p=0.008. 
Key results
Results
Figure 1: Inpatient 
complications of 91,835 
patients with prostate 
cancer treated with 
radical prostatectomy 
(RP) within the NIS from 
2008 to 2014, stratified 
by the presence of 
metastatic disease.
Figure 2: Length of hospital stay in days in 
cytoreductive RP as compared to RP in non-
metastatic disease patients
Figure 3: Inflation adjusted cost in USD in 
cytoreductive RP as compared to RP in non
metastatic disease patients
RP: Radical prostatectomy
• cRP is associated with higher inpatient morbidity, longer 
hospital stay, and higher cost compared to RP for 
nonmetastatic disease. 
• This information may be valuable for informed decision-making 
in practice and before recruiting patients in clinical trials on this 
subject.
Conclusion
